Literature DB >> 8811358

High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients.

D Hober1, S Benyoucef, A S Delannoy, D de Groote, F Ajana, Y Mouton, P Wattré.   

Abstract

Plasma concentrations of soluble receptors for tumor necrosis factor type II (sTNFRII) and CD4+ lymphocyte counts were determined in patients with HIV-1 infection grouped according to the 1993 classification of the CDC. Compared with healthy controls (mean +/- SD = 2.83 +/- 0.70 ng/ml; n = 20), higher values of sTNFRII were obtained in most of patients of all groups of HIV-1-infected patients. The levels of sTNFRII were 5.29 +/- 1.75 ng/ml (n = 23) for stage A1 patients, 5.27 +/- 2.25 ng/ml (n = 37) for stage A2 patients, 6.03 +/- 1.9 ng/ml (n = 14) for stage A3 patients, 7.41 +/- 3.25 ng/ml (n = 21) for stage B and stage C patients. Intra-individual variance in sTNFRII levels in eight clinically stable patients with HIV-1 infection was observed in the course of a short-time follow-up. The increase of sTNFRII plasma levels in five out of ten patients was shown at time lapses of 3 years. In contrast to previous reports no inverse correlation between sTNFRII and CD4+ lymphocyte counts was found in all stages of disease. The increased level of sTNFRII in circulating blood might reflect the activation of the TNF alpha system. These results support an activation of this system occurring early in the course of HIV infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811358     DOI: 10.1007/bf01781095

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  Cytokines and HIV infection: is AIDS a tumor necrosis factor disease?

Authors:  T Matsuyama; N Kobayashi; N Yamamoto
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

Review 2.  The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.

Authors:  A S Fauci
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

3.  Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) in patients with AIDS. Enhanced level of TNF-alpha is related to a higher cytotoxic activity.

Authors:  D Hober; A Haque; P Wattre; G Beaucaire; Y Mouton; A Capron
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

4.  Induction of soluble tumor necrosis factor receptor (sTNF-R75) release by HIV adsorption on cultured human monocytes.

Authors:  A C Rimaniol; F Boussin; A Herbelin; D De Groote; D Dormont; J F Bach; B Descamps-Latscha; F Zavala
Journal:  Eur J Immunol       Date:  1994-09       Impact factor: 5.532

5.  Variation in serum levels of the soluble TNF receptors among healthy individuals.

Authors:  D Aderka; H Engelmann; Y Shemer-Avni; V Hornik; A Galil; B Sarov; D Wallach
Journal:  Lymphokine Cytokine Res       Date:  1992-06

6.  Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection.

Authors:  A Kalinkovich; H Engelmann; N Harpaz; R Burstein; V Barak; I Kalickman; D Wallach; Z Bentwich
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

7.  Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection.

Authors:  M H Godfried; T van der Poll; J Jansen; J A Romijin; J K Schattenkerk; E Endert; S J van Deventer; H P Sauerwein
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

8.  TNF-alpha production by U937 promonocytes is enhanced by factors released from HIV-infected T4 lymphocytes: TNF-alpha is one of the mediators causing lysis of HIV-infected T4 cells.

Authors:  D Hober; B Lucas; P Wattre; A Capron; A Haque
Journal:  Clin Immunol Immunopathol       Date:  1992-02

9.  Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1.

Authors:  P Roux-Lombard; C Modoux; A Cruchaud; J M Dayer
Journal:  Clin Immunol Immunopathol       Date:  1989-03

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more
  5 in total

1.  Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients.

Authors:  F Ajello; R La Licata; M Lodato; F Vitale; F Bonura; R Valenti; M Bruno; N Romano
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

Review 2.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

3.  Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.

Authors:  Nancy Gasper-Smith; Deanna M Crossman; John F Whitesides; Nadia Mensali; Janet S Ottinger; Steven G Plonk; M Anthony Moody; Guido Ferrari; Kent J Weinhold; Sara E Miller; Charles F Reich; Li Qin; Stephen G Self; George M Shaw; Thomas N Denny; Laura E Jones; David S Pisetsky; Barton F Haynes
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

4.  Social Isolation Is Linked to Inflammation in Aging People With HIV and Uninfected Individuals.

Authors:  Ronald J Ellis; Jenny Iudicello; Ni Sun-Suslow; David Grelotti; Mariana Cherner; Erin Morgan; Scott L Letendre; Robert K Heaton
Journal:  J Acquir Immune Defic Syndr       Date:  2021-04-15       Impact factor: 3.771

5.  Colocalization of endogenous TNF with a functional intracellular splice form of human TNF receptor type 2.

Authors:  Christoph Scherübl; Wulf Schneider-Brachert; Stephan Schütze; Thomas Hehlgans; Daniela N Männel
Journal:  J Inflamm (Lond)       Date:  2005-07-04       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.